Extracellular Matrix: a Gatekeeper in the Transition from Dormancy to Metastatic Growth
Overview
Affiliations
Metastases can develop after apparently successful treatment of a primary tumour, sometimes following a period of tumour dormancy that can last for years. However, factors that regulate metastatic tumour dormancy remain poorly understood. Here we review the potential contribution of interactions between tumour cells and the microenvironment in metastatic sites, in regulating tumour dormancy vs. metastatic growth. We focus particularly on the potential role of the extracellular matrix (ECM) in regulating maintenance and release from dormancy. Tumour cells that fail to properly adhere to the ECM may enter a state of dormancy. The molecular and physical composition of the ECM can be affected by tumour cells themselves, as well as multiple stromal cell types. The roles of integrins, fibronectin, and collagen are discussed, as are factors that can change the ECM. A better understanding of the molecular details of the crosstalk between tumour cells and the ECM in secondary sites, and how these regulate the dormant state, may lead to improved therapeutic strategies to induce or maintain disseminated tumour cells in a dormant state, or alternatively to successfully eradicate dormant cells.
Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.
Tufail M, Jiang C, Li N Mil Med Res. 2025; 12(1):7.
PMID: 39934876 PMC: 11812268. DOI: 10.1186/s40779-025-00595-2.
Dilek O, Sevim K, Dilek O World J Clin Cases. 2024; 12(35):6791-6807.
PMID: 39687641 PMC: 11525903. DOI: 10.12998/wjcc.v12.i35.6791.
Implication of the Extracellular Matrix in Metastatic Tumor Cell Dormancy.
Redoute-Timonnier C, Auguste P Cancers (Basel). 2024; 16(23).
PMID: 39682261 PMC: 11639913. DOI: 10.3390/cancers16234076.
Sarangi A, Salem M, Younus M, El-Haroun H, Mahal A, Tripathy L Int J Surg. 2024; 110(12):7508-7527.
PMID: 39411890 PMC: 11634172. DOI: 10.1097/JS9.0000000000002110.
Inflammation drives tumor growth in an immunocompetent implantable metastasis model.
Giles C, Lee J Res Sq. 2024; .
PMID: 39149496 PMC: 11326373. DOI: 10.21203/rs.3.rs-4719290/v1.